AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06397807
Drug: Enteral analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids, NSAIDs or acetaminophen will be prescribed if necessary.
Trial: NCT05130060
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05181865
Drug: 1 mg/kg IV FL-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N = 1
Trial: NCT05181865
Drug: 3 mg/kg IV FL-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N = 3-6
Trial: NCT05181865
Drug: 10 mg/kg IV FL-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N = 3-6
Trial: NCT05181865
Drug: 20 mg/kg IV FL-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N = 3-6
Trial: NCT05181865
Drug: 30 mg/kg IV FL-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N = 3-6
Trial: NCT05181865
Drug: RP2D, IV FL-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic Cancer N = 30
Trial: NCT05181865
Drug: RP2D, IV FL-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric Cancer (Including GEJ) N = 30
Trial: NCT05181865
Drug: RP2D, IV FL-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Solid Tumors N = 30
Trial: NCT05869643
Drug: High-dose STP0404 (Pirmitegravir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral capsule taken after breakfast
Trial: NCT05869643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule, taken orally once daily after breakfast
Trial: NCT05787925
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26 patients will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase three times daily for 8 week that will be applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application
Trial: NCT06629376
Drug: Pegylated Recombinant Candida Utilis Uricase for Injection
RxNorm normalized name: antihemophilic factor (recombinant) pegylated Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
Trial: NCT05030311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04749433
Drug: [11C]CPPC Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
Trial: NCT05905367
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Symptom-inhibited IV fentanyl induction
Trial: NCT04109118
Drug: BZD discontinuation protocol
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 9 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
Trial: NCT05788094
Drug: Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.)~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given.
Trial: NCT04789850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral for 360 days
Trial: NCT04891133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg placebo (2 tablets of 2 mg) once daily
Trial: NCT05039944
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI is administered intravenously at the standard dose recommended by the guidelines(Q2W).
Trial: NCT05039944
Drug: FOLFOX Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX is administered intravenously at the standard dose recommended by the guidelines(Q2W).
Trial: NCT05096117
Drug: ASP8062
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
Trial: NCT05096117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x per day for 6 weeks
Trial: NCT05886582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug
Trial: NCT04727320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo, once a day, one tablet at a time for 6 months
Trial: NCT05001282
Drug: ELU001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
Trial: NCT06162351
Drug: PLX038
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment will be at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection).~Patients with a clinical benefit could be treated as long as study is ongoing. Patients are followed from inclusion until documented disease progression, withdrawal of consent, or death.
Trial: NCT06466473
Drug: Phenytoin (Ascoli)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin 50mg chewable tablets
Trial: NCT06466473
Drug: Phenytoin (Vega Baja)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin 50mg chewable tablets
Trial: NCT04218539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg Diphenhydramine
Trial: NCT04589611
Drug: Placebo (single dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of placebo during the initial surgical intervention
Trial: NCT04589611
Drug: Placebo (two doses)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
Trial: NCT05964257
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
Trial: NCT05944237
Drug: HTL0039732 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0039732 Capsules will be administered orally to fasted participants, although an exploration of food effects may be performed as a single dose at Cycle 0. A single dose will be administered between 3 and 9 days prior to commencement of Cycle 1. From Cycle 1 Day 1, HTL0039732 will be administered on a once daily (QD) schedule. Each administration cycle will consist of 21 days with no break between cycles. Participants may initially receive up to 18 cycles but may continue for a further 18 cycles if they are deemed to be benefitting.
Trial: NCT05576662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours
Trial: NCT05756439
Drug: Intravenous Sedatives with or Without Analgesia
RxNorm normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants having dental surgery with conscious intravenous sedation
Trial: NCT05756439
Drug: No IV sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants having dental surgery without conscious intravenous sedation
Trial: NCT06049108
Drug: [14C]-LY3871801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04966507
Drug: Listerine Antiseptic Mouthwash Product
RxNorm normalized name: Listerine Antiseptic Mouthwash Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
Trial: NCT04966507
Drug: Biotene Mouthwash
RxNorm normalized name: BIOTENE MOUTHWASH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
Trial: NCT06614985
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An intravenous injection of 0.4 g is administered twice a month.
Trial: NCT06614348
Drug: Prednisolone acetate eye drop group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive prednisolone acetate eye drops 4 times per 30min within 2 hours before cataract surgery
Trial: NCT04872595
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (60mg/kg/day x 2 days) Day -3 to -2
Trial: NCT05604131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
Trial: NCT06173570
Drug: AZD0780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0780 administered orally, once daily for 12 weeks
Trial: NCT06173570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally, once daily for 12 weeks
Trial: NCT04775225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group
Trial: NCT04775225
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 80mg of triamcinolone
Trial: NCT06237400
Drug: ZG19018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZG19018 Given by PO (mouth)
Trial: NCT05285540
Drug: DT-216 matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by intravenous (IV) injection
Trial: NCT05722548
Drug: Indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia
Trial: NCT05560152
Drug: Yiqihuayu Decotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per os, twice a day, for 7 days.
Trial: NCT05702398
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg NAM twice a day for 6 months
Trial: NCT05522296
Drug: Mpox Vaccine
RxNorm normalized name: smallpox and mpox vaccine, live, nonreplicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
Trial: NCT06245109
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg, oral
Trial: NCT06245109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, oral
Trial: NCT05839756
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml normal saline will be nebulized preoperatively
Trial: NCT02133885
Drug: Minocycline Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
Trial: NCT05212454
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
Trial: NCT06225635
Drug: Ezerosu(monolayer tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
Trial: NCT06225635
Drug: Ezerosu(double layer tablet)
RxNorm normalized name: aspirin Oral Tablet [Bayer Aspirin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
Trial: NCT05274269
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) tablets for oral administration.
Trial: NCT05252624
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
Trial: NCT05793684
Drug: Period B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 1: AD816 low dose; Week 2: AD816 high dose
Trial: NCT05793684
Drug: Period C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Trial: NCT03660917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
Trial: NCT05037851
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT06508671
Drug: Empty Medication Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take empty medication capsules orally
Trial: NCT06631300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo taper will be given to match the same number of pills administered in each stage of the prednisone taper.
Trial: NCT05535413
Drug: UTD1 combined with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle.
Trial: NCT06409195
Drug: SM-020 1% Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.
Trial: NCT05838664
Drug: No OAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AF Patient who were not exposed to oral anticoagulation
Trial: NCT04945694
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In this group, patients will receive only incremental doses of intravenous fentanyl
Trial: NCT05870670
Drug: NNC0519-0130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously.
Trial: NCT05870670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously.
Trial: NCT05737784
Drug: PRAX-222 - Initial Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRAX-222
Trial: NCT05737784
Drug: PRAX-222 - Initial Ascending Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending doses of PRAX-222
Trial: NCT05225363
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05737784
Drug: PRAX-222 - Optional Ascending Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalation of PRAX-222 dose(s)
Trial: NCT05737784
Drug: PRAX-222 - Fixed Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
Trial: NCT04968574
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical tablets to the experimental arm with no active ingredient
Trial: NCT06629909
Drug: Secretome
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml Injection of secretome for 8 times two weeks apart
Trial: NCT05196581
Drug: Dispersible NaCl powder 10 sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible NaCl powder 10 sessions
Trial: NCT05196581
Drug: Dispersible NaCl powder 5 sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible NaCl powder 5 sessions
Trial: NCT06711575
Drug: Anti-Infective Drugs
RxNorm normalized name: INVESTIGATIONAL ANTI-INFECTIVE DRUGS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
Trial: NCT04843761
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Trial: NCT05833438
Drug: VEN+AZA-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
Trial: NCT04829916
Drug: RMC-035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dosing during 48 hours following cardiac surgery
Trial: NCT04829916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dosing during 48 hours following cardiac surgery
Trial: NCT06711900
Drug: SKB264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT05052983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received either 1 (30 mg) or 2 (2\*30 mg) SC injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
Trial: NCT05231460
Drug: Active Comparator: narcotic regimen with TAP block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain
Trial: NCT05231460
Drug: Active Comparator: narcotic regimen with no TAP block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain
Trial: NCT05286567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (blinded)
Trial: NCT05594407
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
Trial: NCT05144217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per day of placebo
Trial: NCT05144217
Drug: 3x 280 mg per day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsule per day of silimarit
Trial: NCT05144217
Drug: 1x 1120 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 capsule per day of silimarit
Trial: NCT06421597
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisoline 25 mg/day for seven days
Trial: NCT06421597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for seven days
Trial: NCT05088057
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
Trial: NCT05088057
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.